Adjusted EBITDA reached $76M in Q2 2026, with revenue up 4% year-over-year, driven by improved payer mix, RCM collections, and higher acuity. Full-year EBITDA guidance is reaffirmed, and share repurchases continue as the company focuses on tele-hybrid medicine and acquisition opportunities.Based on…
Adjusted EBITDA reached $76M for Q2 2026, with revenue up 4% year-over-year and strong RCM collections, improved payer mix, and higher acuity offsetting lower volumes. Full-year EBITDA guidance is reaffirmed, and share repurchases continue, supported by a strong balance sheet.Based on Pediatrix Med…
Q2 2026 saw 4% revenue growth to $487.8M, with net income of $39.8M and Adjusted EBITDA of $76.4M. Same-unit reimbursement improved, but patient volume declined. Full-year Adjusted EBITDA guidance remains $280M–$300M.Original document: Pediatrix Medical Group, Inc. [MD] SEC 8-K Current Report — Aug…
Pediatrix Medical reported second-quarter 2026 results with revenue of $487.8 million and net income of $39.8 million, or $0.49 per diluted share. On a non-GAAP basis the company reported Adjusted EPS of $0.63 and Adjusted EBITDA of $76.4 million for the quarter. The company reaffirmed full-year 20…
Pediatric healthcare provider Pediatrix Medical Group NYSE:MDwill be reporting earnings this Tuesday before market open. Here’s what to look for.Pediatrix Medical Group beat analysts’ revenue expectations last quarter, reporting revenues of $476.2 million, up 3.9% year on year. It was a very strong…
Pediatrix Medical Group announced that Mary Ann E. Moore will transition from her roles as Executive Vice President, General Counsel, Chief Administrative Officer and Secretary, serving as an advisor through October 31, 2026, and will depart effective that date.Original SEC Filing: Pediatrix Medica…
